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Available online 21 January 2011The management of carotid artery disease has been care-
fully scrutinized over the past thirty years. The choice of
surgery as compared to stenting for carotid disease has
become more controversial with the recent data published
from the CREST trial in the United States. The results from
CREST can be interpreted in different ways, but I believe it
has justified the efficacy and safety of carotid endarterec-
tomy (CEA). This finding is especially true in older patients.
The original clinical trials from the 1980’s and 1990’s
(e.g. NACET and ACAS) demonstrated the value of carotid
endarterectomy as compared to medical management in
preventing TIA and stroke. The limitation of medical
management at the time of publication of these trials was
that aspirin alone was utilized as the sole agent in the
majority of these studies. Our “medicine cabinet” has
becomemuch more diversified and a combination of aspirin,
Plavix, statin agents, b-blockers, and other medications are
now readily available that assist in TIA and stroke preven-
tion in patients with carotid artery disease. In light of the
changes in the available “best” medical therapy, the results
of the earlier clinical trials have been questioned. Many
people have suggested that the carotid artery surgery trials
need to be repeated with the current available medications* Tel.: þ1 708 327 3431; fax: þ1 708 327 3291.
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doi:10.1016/j.ejvs.2010.12.019in order to confirm the value of CEA in preventing TIA and
stroke as compared to medical therapy.
Dr. Lutz and colleagues have brought to light a new issue
that is very concerning to me in their paper, “Best Medical
Therapy Or Wishful Thinking In Carotid Disease? A Single
Centre Audit in Germany.”1 I read with great interest the
findings of their audit in a sophisticated medical system. They
evaluated a prospective data bank of 95 patients treated with
108 CEA’s. They analyzed which medical therapy these
patients were receiving prior to surgical intervention in
a system where primary care physicians and cardiologists are
intimately involved in the care of these patients. Only 54% of
patients were taking a statin agent, and of these patients,
45% still had an elevated LDL level. Only 1 patient had
a HgbA1C value of less than 6 for the 32 patients treated with
diabetes. And, three patients were severely hypertensive
with a systolic blood pressure >180. Most disappointingly,
only four patients were on Plavix. So, the medication
administration is being performed in an inappropriate fashion
when looking at the patients with prescribed medications.
And, the management of their chronic disease is even more
disappointing in terms of the lipid-lowering therapy and
diabetic control. I agree with the conclusion of the authors in
that it would be worthwhile for all of us to audit our own
systems. We may find data that is surprising to us and our
medical counterparts at our individual institutions.
This study highlights the value of carotid artery inter-
ventions to me. If we cannot provide the “best” medicald by Elsevier Ltd. All rights reserved.
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sented in this study, how can we prevent TIA or stroke with
the “best” medical management? The clinical trials can be
repeated with different medications that are updated to
2011. But, can we trust the results if medical therapy
cannot be applied to the general public in a similar fashion
to the controlled environment of a clinical trial? As long as
we can safely prevent TIA and stroke with a carefully
selected CEA or CAS for an individual patient, then we
should continue to provide this form of therapy. I alsothink this study demonstrates to us, as vascular surgeons,
the need to become familiar with a variety of medications
that are valuable for our patients with peripheral arterial
disease.
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